dc.creator | Mitrović, Jelena | |
dc.creator | Divović, Branka | |
dc.creator | Dobričić, Vladimir | |
dc.creator | Čalija, Bojan | |
dc.creator | Vulić, Jelena P. | |
dc.creator | Knutson, Daniel E. | |
dc.creator | Cook, James M. | |
dc.creator | Savić, Miroslav | |
dc.creator | Savić, Snežana | |
dc.date.accessioned | 2024-02-19T14:02:09Z | |
dc.date.available | 2024-02-19T14:02:09Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/5542 | |
dc.description.abstract | Deuterated pyrazoloquinolinones, GABAn receptor ligands, are being investigated for neuropsychiatric disorders treatment. Among others, DK-l-56-1 (7-Methoxy-2-(4-methoxy-d3- p h e n yl ) - 2, 5 -d i h yd ro - 3 H - py r azolo -14,3 -clq u i n o I i n - 3-one) was chosen as the lead component [1]. Because of its low solubility in water (6.27 t0.74 pg/ml) nanosuspension formulation for prospective parenteral administration was carried out [2]. ... | sr |
dc.language.iso | en | sr |
dc.rights | restrictedAccess | sr |
dc.source | 10th International Congress Nanotechnology in Medicine & Biology, 15 - 17. April 2019, Graz / Austria | sr |
dc.title | Nanonization of new patent protected substances - carrier selection for preclinical research: physicochemical and in vivo behavioral characterization | sr |
dc.type | conferenceObject | sr |
dc.rights.license | ARR | sr |
dc.description.other | BioNanoMed 2019 | sr |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_farfar_5542 | |
dc.type.version | publishedVersion | sr |